Nuclear medicine and biology最新文献

Purpose

Methods

Results

Conclusion

Purpose

Methods

Results

Conclusions

Background

Heterotopic ossification (HO) is the formation of bone within soft tissue where bone normally does not exist. In general, it is characterized by highly active tissue with high bone turnover and rapid bone formation. It is of an utmost importance to precisely identify and accurately diagnose the maturity of HO as early surgical intervention may result in its recurrence. The objective of this work is the experimental evaluation of HO maturity stage using advanced noninvasive nuclear medicine techniques. The use of PET radiopharmaceuticals may result in a more specific diagnosis between the phases due to their higher sensitivity and better resolution compared to bone scan.

Method

8-week-old Balb/c male mice underwent dual injury procedure, tenotomy and concurrent burn injury on the left side, to induce HO. The progression of HO was monitored by SPECT/CT and PET/CT weekly imaging with ^99mTc-MDP, [¹⁸F]NaF and [¹⁸F]FDG for up to 16 weeks.

Results

There was a statistically significant increase of [¹⁸F]FDG uptake from week 1 to 2 and from week 2 to 6 with p values of 0.01 and 0.005; respectively, while there was a statistically significant decrease from week 7 to 14 with a p value of 0.008. There was a statistically significant increase of [¹⁸F]NaF uptake from week 2 to 5 and statistically significant decrease between weeks 7 and 14 with p values of 0.016 and 0.003; respectively. As for ^99mTc-MDP, the increase in the uptake from week 1 to 2 and from week 2 to 5 were not statistically significant with p values of 0.15 and 0.19; respectively. The decrease of uptake between week 7 and 14 was not statistically significant with a p value of 0.08.

Conclusion

Based on these findings, the use of noninvasive nuclear imaging modalities may assist in distinguishing between the immature and mature phases. The uptake of mainly [¹⁸F]FDG may indicate the early inflammatory phase, while the uptake of both [¹⁸F]FGD and [¹⁸F]NaF may suggest the immature phase, and an uptake of mainly [¹⁸F]NaF may indicate the maturity phase of HO.

Purpose

M2-type tumor-associated macrophages (TAM) residing in the tumor microenvironment (TME) have been linked to tumor invasiveness, metastasis and poor prognosis. M2 TAMs suppress T cell activation, silencing the recognition of the cancer by the immune system. Targeting TAMs in anti-cancer therapy may support the immune system and immune-checkpoint inhibitor therapies to fight the cancer cells. We aimed to develop a PET tracer for the imaging of M2 TAM infiltration of cancer, using activated legumain as the imaging target.

Basic procedures

Two P1-mimicking inhibitors with a cyano-warhead were labeled with carbon-11 and evaluated in vitro and in vivo with a CT26 tumor mouse model. Target expression and activity were quantified from RT-qPCR and in vitro substrate conversion, respectively. The co-localization of legumain and TAMs was assessed by fluorescence microscopy. The two tracers were evaluated by PET with subsequent biodistribution analysis with the dissected tissues. Parent-to-total radioactivity in plasma was determined at several time points after i.v. tracer injection, using reverse phase radio-UPLC.

Main findings

Legumain displayed a target density of 40.7 ± 19.1 pmol per mg total protein in tumor lysate (n = 4) with high substrate conversion and colocalization with M2 macrophages in the tumor periphery. [¹¹C]1 and [¹¹C]2 were synthesized with >95 % radiochemical purity and 12.9–382.2 GBq/μmol molar activity at the end of synthesis. We observed heterogeneous tumor accumulation in in vitro autoradiography and PET for both tracers. However, excess unlabeled 1 or 2 did not compete with tracer accumulation. Both [¹¹C]1 and [¹¹C]2 were rapidly metabolized to a polar radiometabolite in vivo.

Principal conclusions

The legumain tracers [¹¹C]1 and [¹¹C]2, synthesized with high radiochemical purity and molar activity, accumulate in the legumain-positive CT26 tumor in vivo. However, the lack of competition by excess compound questions their specificity. Both tracers are rapidly metabolized in vivo, requiring structural modifications towards more stable tracers for further investigations.

Direct fluorination of a tosylate or mesylate precursor has been a wide-spread and reliable way for radio-fluorination. This approach can be difficult to achieve when the precursor cannot be easily obtained or is chemically unstable. A possible alternative method is to radiolabel ethylene ditosylate or 1,3-propanediol di-p-tosylate to form a radiofluorinated synthon. Here we present the automation of a simplified and reliable approach for the two-step fluorination using [¹⁸F]FP-TMP, an analog of antibacterial agent trimethoprim. We demonstrate the feasibility of purifying the fluorinated synthon via filtration, and one final HPLC purification on a commercially available Trasis AllinOne module. The overall reaction time for the two-step reaction is around 90 min andthe decay-corrected yield for more than fifty preparations of [¹⁸F]FP-TMP is 22 ± 5 % with high radiochemical purity (≥ 90 %) and specific activities (147 ± 107 GBq/μmol). All batches passed pre-established quality control specifications, demonstrating the utility of using this method in tracer syntheses that meet good manufacturing practice (GMP) requirement. This method can be adopted to the syntheses of other radiotracers, such as [¹⁸F]FE-TMP, (+)-[¹⁸F]F-PHNO and [¹⁸F]FFMZ.

Radiometals play an important role in nuclear medicine, both for imaging and therapy. Binding studies represent an important step in the development of new radiolabeled ligands, as valuable insights into the binding properties can be gained. However, this technique requires high radiochemical purity, otherwise results may lead to wrong assumptions or misinterpretations of affinities or uptake rates.

Therefore, this in vitro study aimed at investigating the cell binding and internalization characteristics of different radiometal chlorides ([¹¹¹In]InCl₃, [⁶⁸Ga]GaCl₃ and [¹⁷⁷Lu]LuCl₃) commonly applied in nuclear medicine, as well as the clinically applied [¹⁷⁷Lu]Lu-PSMA-I&T in comparison, by using prostate cancer cells. PC-3 and LNCaP cells were incubated with 100 kBq of the respective radiometal chloride or [¹⁷⁷Lu]Lu-PSMA-I&T for 1 h. For [¹⁷⁷Lu]LuCl₃, nuclei isolations and colloid determinations in saline and cell medium were also performed.

Results showed that [¹¹¹In]InCl₃ and [⁶⁸Ga]GaCl₃ bind and are internalized up to 3 % to PC-3 and LNCaP cells, whereas [¹⁷⁷Lu]LuCl₃ showed cell binding of up to 25 %, internalization up to 2.5 % and a nuclear uptake below 0.3 %. In comparison, [¹⁷⁷Lu]Lu-PSMA-I&T showed only 3 % total cell binding to LNCaP cells. Further analysis of [¹⁷⁷Lu]LuCl₃ stability in NaCl and cell medium showed only low amounts of colloids, which are not increasing over time, and negligible unspecific binding to the used cell culture plates.

In conclusion, the results demonstrate the importance of high radiochemical purity, especially with regard to Lu-177 labeled compounds. Even if radiopharmaceuticals comply with common release-criteria, significant uptake can be derived from [¹⁷⁷Lu]LuCl₃ impurities and lead to wrong estimations of a compound's uptake behavior. Assuming an experimental result of 2 % membrane binding of the applied product, and 5 % residual [¹⁷⁷Lu]LuCl₃ in the final product (thereof 25 % membrane binding, as described above), would lead to 1.25 % membrane binding resulting from [¹⁷⁷Lu]LuCl₃ and only 0.75 % from the radiopharmaceutical.